Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6056854 | 0.78 | — | — | |
| SCHEMBL4570555 | 0.77 | SORT1 (0.40) | HRH4CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4625173 | 0.74 | — | — | |
| SCHEMBL396081 | 0.71 | MAPK8 (0.32) | — | |
| SCHEMBL11847450 | 0.69 | KDR (0.36) | AURKASYK | |
| SCHEMBL20306489 | 0.68 | CYP1A2 (0.56) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5632484 | 0.68 | ROCK1 (0.38) | AURKAROCK1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL4884433 | 0.68 | AURKA (0.65) | AURKASYKROCK1 | |
| SCHEMBL11964357 | 0.67 | RXFP1 (0.39) | CYP1A2 | |
| SCHEMBL20325387 | 0.67 | NPC1 (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120259106-A1 | ASYNTHESIS OF B-NUCLEOSIDES | PHARMAESSENTIA CORP. (TW) | 2012-10-11 | — | — | US | disclosed |
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259106-A1 | ASYNTHESIS OF B-NUCLEOSIDES | ATIC, DPYD, DUT | AURKA 2937/4885SYK 3528/4885HRH4 3199/4885 |
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | NUDT1, NT5C3B, NTPCR | AURKA 3517/4885SYK 4754/4885HRH4 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.